دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Predicting heart failure in atrial fibrillation patients: What about using biomarkers?☆
Raquel López-Gálvez, PhD 1 , Francisco MarÃn, MD, PhD 1 , and José Miguel Rivera-Caravaca, RN, PhD 1,2 Murcia, Spain
doi : 10.1016/j.ahj.2022.05.007
Volume 251, September 2022, Pages 32-34
The efficacy of single-lead implantable cardioverter-defibrillator with atrial sensing dipole to detect atrial fibrillation and to reduce inappropriate therapy according to atrial sensing ON or OFF: Rationale and design of the SMART-CONTROL study, a prospective multicenter randomized trial
Hye Bin Gwag, MD a,# , Hye Ree Kim, MD b , Seung-Jung Park, MD b , Juwon Kim, MD b , Tae Wan Chung, MD b , Ji-Hoon Choi, MD b , Ju Youn Kim, MD b , Kyoung-Min Park, MD b , Young Keun On, MD b , and June Soo Kim, MD b Changwon, Republic of Korea; Seoul, Republic of Korea
doi : 10.1016/j.ahj.2022.05.008
Volume 251, September 2022, Pages 25-31
Comparison of anticoagulation with left atrial appendage closure after atrial fibrillation ablation: Rationale and design of the OPTION randomized trial
Oussama M. Wazni, MD a , Lucas Boersma, MD b , Jeff S. Healey, MD c , Moussa Mansour, MD d , Claudio Tondo, MD e , Karen Phillips, MBBS f , Rahul Doshi, MD g , Wael Jaber, MD h , Erin Hynes, MS i , Dominic J. Allocco, MD i , and Vivek Y. Reddy, MD j Cleveland, OH; Amsterdam, The Netherlands; Ontario, Canada; Boston, MA; Milan, Italy; Brisbane, Australia; Scottsdale, AZ; Marlborough, MA; New York, NY
doi : 10.1016/j.ahj.2022.05.003
Volume 251, September 2022, Pages 35-42
Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study
Frederikus A. Klok, MD a,g , Gregory Piazza, MD b , Andrew S.P. Sharp, MD c , Fionnuala NÃ Ainle, MD d , Michael R. Jaff, DO e , Nikhil Chauhan, PhD e , Binal Patel, MPH e , Stefano Barco, MD f,g , Samuel Z. Goldhaber, MD b , Nils Kucher, MD f , Irene M. Lang, MD h , Irene Schmidtmann, PhD i , Keith M. Sterling, MD j , Dorothea Becker, PhD g , Nadine Martin, PhD g , Kenneth Rosenfield, MD k , and Stavros V. Konstantinides, MD g,l,1 Leiden, The Netherlands; MA, USA; Cardiff, United Kingdom; Dublin, Ireland; Massachusetts, USA; Zurich, Switzerland; Mainz, Germany; Vienna, Austria; Mainz, Germany; VA, USA; Greece
doi : 10.1016/j.ahj.2022.05.011
Volume 251, September 2022, Pages 43-53
Due to the bleeding risk of full-dose systemic thrombolysis and the lack of major trials focusing on the clinical benefits of catheter-directed treatment, heparin antiocoagulation remains the standard of care for patients with intermediate-high-risk pulmonary embolism (PE).
A randomized multicenter trial to evaluate early invasive strategy for patients with acute ST-segment elevation myocardial infarction presenting 24-48 hours from symptom onset: Protocol of the RESCUE-MI study
Wei Gao, PhD a,# , Xin Zhong, PhD a,# , Yuanji Ma, PhD a,# , Dong Huang, PhD a , Ruochen Wang, PhD a , Shihai Zhao, MD b , Shan Yang, PhD b , Juying Qian, PhD a , and Junbo Ge, PhD a Shanghai, China
doi : 10.1016/j.ahj.2022.05.002
Volume 251, September 2022, Pages 54-60
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)
Michelle L. O’Donoghue, MD, MPH a , J. Antonio G. López, MD b , Beat Knusel, PhD b , Baris Gencer, MD c,d , Huei Wang, PhD b , You Wu, PhD b , Helina Kassahun, MD b , and Marc S. Sabatine, MD, MPH a Boston, MA and Thousand Oaks, CA
doi : 10.1016/j.ahj.2022.05.004
Volume 251, September 2022, Pages 61-69
Rationale and design of switch Swedeheart: A registry-based, stepped-wedge, cluster-randomized, open-label multicenter trial to compare prasugrel and ticagrelor for treatment of patients with acute coronary syndrome
Elmir Omerovic, MDPhD a,b , David Erlinge, MDPhD c , Sasha Koul, MDPhD c , Ole Frobert, MDPhD d,e , Jonas Andersson, MDPhD f , Johan Ponten, MDPhD g , Fredrik Björklund, MDPhD h , Robert Kastberg, MDPhD h , Max Petzold, PhD i , Charlotta Ljungman, MDPhD a,b , Kristian Bolin, PhD j , and Björn Redfors, MDPhD a,b Gothenburg, Gothenburg, Lund, Aarhus, Halmstad, Gothenburg
doi : 10.1016/j.ahj.2022.05.017
Volume 251, September 2022, Pages 70-77
Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study
Stephen J. Greene, MD a , Dominik Lautsch, PhD b , Hanna K. Gaggin, MD, MPH c , Laurence M. Djatche, PharmD MS b , Mo Zhou, PhD d , Yan Song, PhD d , James Signorovitch, PhD d , Andra S. Stevenson, PhD b , Robert O. Blaustein, MD, PhD b , and Javed Butler, MD, MPH, MBA e Durham, NC; Rahway, NJ; Boston, MA; Dallas, TX; Jackson, MS
doi : 10.1016/j.ahj.2022.05.016
Volume 251, September 2022, Pages 127-136
Patients with heart failure with reduced ejection fraction (HFrEF) and worsening HF events (WHFE) represent a distinct subset of patients with a substantial comorbidity burden, greater potential for intolerance to medical therapy, and high risk of subsequent death, hospitalization and excessive healthcare costs.
Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial
Warren J. Cantor, MD a , Mary Tan, MSC b , Otavio Berwanger, MD, PHD s , Shahar Lavi, MD d , Harvey D. White, MD, DSC e , Jose C. Nicolau, MD, PHD f , Payam Dehghani, MD g , Carlos D. Tajer, MD, PHD h , Renato D. Lopes, MD, MHS, PHD i,j , Diogo D.F. Moia, PHARMD c , Stephen J. Nicholls, MD, PHD k , Alexander Parkhomenko, MD, PHD l , Oleg Averkov, MD, PHD m , Neil Brass, MD n , Sohrab Lutchmedial, MDCM o,1 , Germán Malaga, MD p , Lucas P. Damiani, MSC c , Leopoldo S. Piegas, MD, PHD q , Christopher B. Granger, MD, PHD i , and Shaun G. Goodman, MD, MSC r Ontario, Canada; Sao Paulo, Brazil; Auckland, New Zealand; Saskatchewan, Canada; Buenos Aires, Argentina; Durham, North Carolina; Victoria, Australia; Kiev, Ukraine; Moscow, Russia; Alberta, Canada; Nova Scotia, Canada; Lima, Peru;
doi : 10.1016/j.ahj.2022.05.005
Volume 251, September 2022, Pages 1-12
Morphine is commonly used to relieve pain, anxiety and dyspnea in STEMI but it lowers blood pressure and delays the activity of oral antiplatelet agents. The impact of morphine on clinical outcomes remains unknown.
Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model
Julia Aulin, MD, PhD a,b , Ziad Hijazi, MD, PhD a,b , Johan Lindbäck, MSc b , John H. Alexander, MD, MHS c , Bernard J. Gersh, CHB, DPHIL, MB, MACC d , Christopher B. Granger, MD c , Michael Hanna, MD e , John Horowitz, MD, PhD f , Renato D. Lopes, MD, PhD c , John J.V. McMurray, MD g , Jonas Oldgren, MD, PhD a,b , Agneta Siegbahn, MD, PhD b,h , and Lars Wallentin, MD, PhD a,b , on behalf of the ARISTOTLE Investigators Sweden; Durham, NC; Rochester, MN; Princeton, NJ; SA, Australia; Scotland, United Kingdom; Uppsala, Sweden
doi : 10.1016/j.ahj.2022.03.009
Volume 251, September 2022, Pages 13-24
Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease
Faizan Mazhar, PharmD, PhD, BCPS a , Paul Hjemdahl, MD, PhD, FESC, FAHA b , Catherine M Clase, MD, PhD c , Kristina Johnell, Pharm, PhD a , Tomas Jernberg, MD, PhD, FESC d , and Juan Jesus Carrero, Pharm, PhD d Stockholm, Sweden; Ontario, Canada
doi : 10.1016/j.ahj.2022.05.021
Volume 251, September 2022, Pages 78-90
To examine patterns of lipid-lowering therapy (LLT) use, and persistence and adherence among patients with coronary heart disease and their associations with lipoprotein cholesterol (LDL-C) goal attainment.
Longer term benefits of exercise and escitalopram in the treatment of anxiety in patients with coronary heart disease: Six month follow-up of the UNWIND randomized clinical trial
James A. Blumenthal, PhD a , Patrick J. Smith, PhD a , Wei Jiang, MD a , Alan Hinderliter, MD b , Lana L. Watkins, PhD a , Benson M. Hoffman, PhD a , William E. Kraus, MD c , Stephanie Mabe, MS a , Lawrence Liao, MD c , Jonathan Davidson, MD a , and Andrew Sherwood, PhD a Durham, NC; Chapel Hill, NC
doi : 10.1016/j.ahj.2022.05.014
Volume 251, September 2022, Pages 91-100
Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis
Dae Yong Park, MD a,1 , Peter Wang, MD b,1 , Seokyung An, BS c , Alyssa A. Grimshaw, MSLIS d , Jennifer Frampton, DO, MPH e , E Magnus Ohman, MBBS f , Sunil V. Rao, MD f , and Michael G. Nanna, MD, MHS e Chicago, New Haven, Korea, New Haven, New Haven, Durham
doi : 10.1016/j.ahj.2022.05.019
Volume 251, September 2022, Pages 101-114
The decision to shorten the duration of DAPT following PCI in patients with ACS remains controversial because of the concern for increased ischemic events.
Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial
Jacob B. Pierce, MD, MPH a , Robert J. Mentz, MD a,b , Jie-Lena Sun, MS b , Brooke Alhanti, PhD b , David J. Whellan, MD, MHS c , William E. Kraus, MD d , Ileana L. Piña, MD, MPH c , Mona Fiuzat, PharmD a , Christopher M. O’Connor, MD e , and Stephen J. Greene, MD a,b Durham, Durham, Philadelphia, Durham, Falls Church
doi : 10.1016/j.ahj.2022.05.018
Volume 251, September 2022, Pages 115-126
